Chemistry: molecular biology and microbiology – Micro-organism – per se ; compositions thereof; proces of... – Bacteria or actinomycetales; media therefor
Patent
1987-08-24
1992-11-10
Peet, Richard C.
Chemistry: molecular biology and microbiology
Micro-organism, per se ; compositions thereof; proces of...
Bacteria or actinomycetales; media therefor
435 691, 435 712, 435 91, 4351721, 4351723, 4353201, 435879, 435885, 424 88, 424 93A, 536 27, 935 6, 935 9, 935 12, 935 22, 935 29, 935 59, 935 60, 935 61, 935 66, 935 72, C12N 121, C12N 1531, C12N 1509, A01N 6300
Patent
active
051622262
ABSTRACT:
Non-virulent aro-Salmonella typhimurium bacterium is disclosed into which has been cloned a heterologous nucleotide sequence encoding for the expression of Streptococcal M protein antigen from S. pyogenes seratype 5, which is effective to elicit opsonic antibodies against Streptococcal infections. The bacterium is useful for vaccination against Streptococcus pyogenes bacteria.
REFERENCES:
patent: 4454121 (1984-06-01), Beachey et al.
patent: 4550081 (1985-10-01), Stocker
patent: 4597967 (1986-07-01), Beachey
patent: 4735801 (1988-04-01), Stocker
patent: 4784948 (1988-11-01), Scott et al.
patent: 4919930 (1990-04-01), Beachey et al.
Poirer et al. Infection and Immunity vol. 48 198-203 (1985).
Kehoe et al., Infection and Immunity vol. 48 190-198 (1985).
Protection Against Streptococcal Pharyngeal Colonization with a Vaccina: Science, vol. 244, pp. 1487-1490, Fischetti et al.
Typoid Fever, Bacterial Vaccines, Ch. 5, 137-65 (1984), Academic Press, Inc., Germanier.
An Attenuated aroA Salmonella typhimurium Vaccine Elicts Humoral and Celular Immunity to Cloned B-Galactosidase in Mice, Journal of Inf. Dis.
Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines, Hoiseth & Stocker, Nature, vol. 291, May 1981.
In-Vivo Immunostimulating Activity of the 163-171 Peptide of Human Nencioni L. et al., J. Immunol 139 (30) 1987, 800-804.
Primary Prophylaxis of Rheumatic Fever State and Prospects Vaccine Inst. Hyg. Epidemiol., Prague, Czech, Ter Arkh 57 (11) 1985, 97-100.
Expression of Mycobacterium-Leprae Genes from a Streptococcus-Mutans Jacobs W. R. et al., Proc. Natl. Acad. Sci. USA 83 (6) 1986, 1926-1930.
In-Vivo Repackaging of Recombinant Cosmid Molecules for Analysis of Salmonella-Typhimurium Strptococcus-Mutans and Mycobacerial Genomic Jacobs W. R., Infect. Immun., 52 (10) 1986 101-109.
Use of Muramyl Dipeptides in the Synthetic Vaccine Models Audibert F., Boll 1st Sieroter Milan, 64 (2). 1985. 95-102.
Molecular Analysis of DNA and Construction of Genomic Libraries of . . . Clark-Curtiss J. E. et al., J. Bacteriol 161 (3). 1985, 1093-1102.
Mono Clonal Antibodies to Streptococcal Group A Carbohydrate 2 . . . Fulton R. J. et al., J. Immunol., 131 (3). 1983. 1326-1331.
Cloning Virulence Determinants from Streptococcus Mutans and the use Hamada, Mol. Microbiol, 1986., 173-80.
Beachey Edwin H.
Kehoe Michael A.
Poirier Thomas P.
Peet Richard C.
University of Tennessee Research Corp. (U.T.R.C.)
LandOfFree
Therapeutic compositions against streptococcal infections, trans does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic compositions against streptococcal infections, trans, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic compositions against streptococcal infections, trans will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2291912